bivalent gii.4/gi.1
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 15, 2022 (NCT05626803)
Timeline
Indications
Mechanism of action
- NorovirusImmunity, active
Norovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05916326 | Phase 3 | Jun 30, 2023 | China National Biotec Group Co., Ltd, National Vaccine and Serum Institute, China |
| NCT05626803 | Phase 2 | Dec 15, 2022 | Vaxart |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China National Biotec Group Co., Ltd | For profit | 1 | 0 | 1 | 2023 |
| National Vaccine and Serum Institute, China | For profit | 1 | 1 | 1 | 2023 |
| Vaxart | For profit | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1